Results 81 to 90 of about 46,918 (102)

Editorial

Kartografija i Geoinformacije, 2008
Miljenko Lapaine
doaj  

Slavonia - History of the Settlements and the Origins of Inhabitants, Mirko Marković

Kartografija i Geoinformacije, 2013
Ivka Kljajić
doaj  

Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells [PDF]

Cancers, 2019
International audienceGA101/obinutuzumab is a novel type II anti-CD20 monoclonal antibody (mAb), which is more effective than rituximab (RTX) in preclinical and clinical studies when used in combination with chemotherapy.
Simon Latour, Pierre Vacher, Ariel Savina   +2 more
exaly   +3 more sources

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101 [PDF]

Molecular Cancer Therapeutics, 2011
International audienceGA101 is a novel glycoengineered Type II CD20 monoclonal antibody. When compared with rituximab, it mediates less complement-dependent cytotoxicity (CDC).
Christian Klein, , Charles Dumontet
exaly   +2 more sources

Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101 [PDF]

Leukemia Research, 2017
International audienceGA101, also known as obinutuzumab or Gazyva (Gazyvaro), is a glycoengineered type II humanized antibody that targets the CD20 antigen expressed at the surface of B-cells.
Abdel Aouacheria, Jérôme Kucharczak, Gilles A Salles   +2 more
exaly   +3 more sources

Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study [PDF]

Journal of Clinical Oncology, 2013
International audiencePurposeObinutuzumab (GA101), a type II, glycoengineered, humanized anti-CD20 monoclonal antibody, was superior to rituximab in human diffuse large B-cell lymphoma (DLBCL) and mantle-cell lymphoma (MCL) xenograft models.
Catherine Thieblemont, Guillaume Cartron, Michael Wenger   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption

Dermatology and Therapy, 2012
Ian H Coulson
exaly  

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

Leukemia and Lymphoma, 2014
Christian Klein, Pablo Umana, Thomas Friess   +2 more
exaly  

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

Blood, 2014
, Guillaume Cartron, Dilhuydy Marie-Sarah   +2 more
exaly  

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Molecular Cancer Therapeutics, 2013
Christian Klein, Sylvia Herter, Charles Dumontet   +2 more
exaly